[{"id":"ce2ff0b0-99e6-4f9c-b3b5-b6907b1b16fa","acronym":"EECBL","url":"https://clinicaltrials.gov/study/NCT02728882","created_at":"2021-01-18T13:21:32.021Z","updated_at":"2024-07-02T16:37:24.154Z","phase":"","brief_title":"Study Evaluating the Efficacy and Safety With CAR-T for Recurrent or Refractory Diffuse Large B Cell Lymphoma","source_id_and_acronym":"NCT02728882 - EECBL","lead_sponsor":"Sinobioway Cell Therapy Co., Ltd.","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19-targeted CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 24","initiation":"Initiation: 07/02/2015","start_date":" 07/02/2015","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2019","study_completion_date":" 07/01/2019","last_update_posted":"2017-03-23"}]